Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.

Donate to our crowdfunder

Novartis

Department of Health written question – answered on 11th December 2017.

Alert me about debates like this

Photo of Melanie Onn Melanie Onn Shadow Minister (Housing)

To ask the Secretary of State for Health, what assessment his Department has made of the potential effect of the relocation of the European Medicines Agency on the future of the Novartis pharmaceutical (a) site and (b) production at that site.

Photo of Steve Brine Steve Brine The Parliamentary Under-Secretary of State for Health

The Government is committed to ensuring a positive outcome for the whole life science sector that enhances competitiveness and builds on the success that we are rightly proud of, as we exit the European Union. Officials across government have been carrying out a programme of sectoral and regulatory analysis to identify the key factors for the life sciences sector that will affect our negotiations with the EU. Ultimately it is for the European Medicines Agency to comment on how it intends to operate from its new location, and what individual companies like Novartis might have to do differently.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.